Iovance Biotherapeutics
Stock Forecast, Prediction & Price Target
Iovance Biotherapeutics Financial Estimates
Iovance Biotherapeutics Revenue Estimates
Iovance Biotherapeutics EBITDA Estimates
Iovance Biotherapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $0 0% | $1.18M 0% | Avg: $411.13M Low: $411.13M High: $411.13M avg. 34478.10% | Avg: $647.63M Low: $647.63M High: $647.63M avg. 57.52% | Avg: $1.04B Low: $1.04B High: $1.04B avg. 61.06% | Avg: $1.37B Low: $1.37B High: $1.37B avg. 31.78% |
Net Income
% change YoY
| $-342.25M N/A | $-395.89M -15.67% | $-444.03M -12.16% | Avg: $-168.56M Low: $-168.56M High: $-168.56M avg. 62.03% | Avg: $-4.07M Low: $-4.07M High: $-4.07M avg. 97.58% | Avg: $183.79M Low: $183.79M High: $183.79M avg. 4610.50% | Avg: $366.80M Low: $366.80M High: $366.80M avg. 99.57% |
EBITDA
% change YoY
| $-328.72M N/A | $-377.74M -14.91% | $-449.01M -18.86% | Avg: $246.68M Low: $246.68M High: $246.68M avg. 154.93% | Avg: $388.58M Low: $388.58M High: $388.58M avg. 57.52% | Avg: $625.86M Low: $625.86M High: $625.86M avg. 61.06% | Avg: $824.77M Low: $824.77M High: $824.77M avg. 31.78% |
EPS
% change YoY
| -$2.23 N/A | -$2.49 -11.65% | -$1.89 24.09% | Avg: -$0.72 Low: -$0.72 High: -$0.72 avg. 62.06% | Avg: -$0.02 Low: -$0.02 High: -$0.02 avg. 97.58% | Avg: $0.78 Low: $0.78 High: $0.78 avg. 4610.50% | Avg: $1.56 Low: $1.56 High: $1.56 avg. 99.57% |
Operating Expenses
% change YoY
| $328.72M N/A | $377.74M 14.91% | $450.99M 19.39% | Avg: $6.17B Low: $6.17B High: $6.17B avg. 1269.34% | Avg: $9.72B Low: $9.72B High: $9.72B avg. 57.52% | Avg: $15.66B Low: $15.66B High: $15.66B avg. 61.06% | Avg: $20.64B Low: $20.64B High: $20.64B avg. 31.78% |
FAQ
What is Iovance Biotherapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 1217.42% in 2025-2028.
We have gathered data from N/A analysts. Their low estimate is -168.56M, average is -168.56M and high is -168.56M.
What is Iovance Biotherapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 8657.11% in 2025-2028.
We have gathered data from N/A analysts. Their low revenue estimate is $411.13M, average is $411.13M and high is $411.13M.
What is Iovance Biotherapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 1217.43% in 2025-2028.
We have gathered data from N/A analysts. Their low earnings per share estimate is -$0.72, average is -$0.72 and high is $-0.71.